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Abstract
The development of heart failure (HF) is characterized by progressive alteration of left ventricle structure and function. Previous works on prote-
omic analysis in cardiac tissue from patients with HF remain scant. The purpose of our study was to use a proteomic approach to investigate
variations in protein expression of left ventricle tissue from patients with ischaemic (ICM) and dilated cardiomyopathy (DCM). Twenty-four ex-
planted human hearts, 12 from patients with ICM and 12 with DCM undergoing cardiac transplantation and six non-diseased donor hearts
(CNT) were analysed by 2DE. Proteins of interest were identified by mass spectrometry and validated by Western blotting and immunofluores-
cence. We encountered 35 differentially regulated spots in the comparison CNT versus ICM, 33 in CNT versus DCM, and 34 in ICM versus
DCM. We identified glyceraldehyde 3-phophate dehydrogenase up-regulation in both ICM and DCM, and alpha-crystallin B down-regulation in
both ICM and DCM. Heat shock 70 protein 1 was up-regulated only in ICM. Ten of the eleven differentially regulated proteins common to both
aetiologies are interconnected as a part of a same network. In summary, we have shown by proteomics analysis that HF is associated with
changes in proteins involved in the cellular stress response, respiratory chain and cardiac metabolism. Although we found altered expression of
eleven proteins common to both ischaemic and dilated aetiology, we also observed different proteins altered in both groups. Furthermore, we
obtained that seven of these eleven proteins are involved in cell death and apoptosis processes, and therefore in HF progression.
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Introduction
Heart failure (HF) is a progressive disorder characterized by poor
prognosis and quality of life. It constitutes a major public health bur-
den in the western world. This complex syndrome consists of not
only haemodynamic abnormalities, but also cellular and molecular
alterations in cardiac tissue. The development of chronic HF is char-
acterized by progressive alteration of left ventricle structure and func-
tion, but the mechanism of these changes is still unclear and remains
under intense study. Proteomic studies can serve as a preliminar
approach of focused biochemical and physiological design to confirm
changes associated not only with cardiovascular dysfunction but also
with pharmacological interventions taken in response to this dysfunc-
tion.
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To date, most studies on HF in human cardiomyocytes have
focused on alterations in specific candidate proteins that have an
important role in its physiopathology [1–3]. Moreover, differential
proteomic approach has been applied to the search for novel proteins
involved in the diseased heart, providing a new insight into the cellu-
lar mechanisms implied in cardiac dysfunction, and, furthermore offer
the possibility of understanding the function of the cardiovascular
system in all of its complexity [4–9]. In recent years, several studies
based on the proteomic analysis of the left ventricle in animal models
of heart disease or HF have shown changes in proteins involved in
cardiac metabolism, associated with mitochondria and energy pro-
duction, stress responses and structural proteins [10–13]. However,
previous works on the proteomic analysis of left ventricular tissue
from patients with ischaemic and dilated cardiomyopathy remain
scant [7–9]. In fact, there is one recent proteomic study performed
on human left ventricular tissue, but only from patients with DCM [9].
We hypothesize that patients with HF present different changes in
left ventricular protein expression involved in essential cellular mech-
anisms according to the aetiologic diagnosis. The purpose of our
study was therefore to use a proteomic approach to investigate varia-
tions in protein expression of left ventricle tissue from patients with
ICM and DCM. We identified several proteins involved in the mito-
chondrial respiratory chain, associated with stress response, related
with cellular metabolism and structural proteins, as potential cellular
biomarkers for HF. We focused on three proteins with different
expression between control and diseased, and found that glyceralde-
hyde 3-phophate dehydrogenase (G3P), heat shock 70 protein 1
(HSP71) and alpha-crystallin B (CRYAB) could have an important role
in these cardiomyopathies.
Materials and methods
Collection of samples
Experimental material was taken from 24 explanted human hearts, 12
from patients with ICM and 12 with DCM undergoing cardiac transplan-
tation. Clinical history, haemodynamic studies, electrocardiogram, Dopp-
ler echocardiography and coronary angiography data were available on
all these patients. All patients were functionally classified according to
the New York Heart Association (NYHA) criteria and were receiving
medical treatment following the guidelines of the European Society of
Cardiology [14], with diuretics 92%, aldosterone antagonists 83%, b-
blockers 75%, angiotensin-converting enzyme inhibitors 68%, digoxin
50% and statins 42%. Non-ischaemic DCM was diagnosed when
patients had intact coronary arteries on coronary angiography and left
ventricular systolic dysfunction (ejection fraction <40%) with a dilated
non-hypertrophic left ventricle (left ventricular diastolic diame-
ter >55 mm) on echocardiography. We have chosen patients with DCM
without family history of this pathology. Furthermore, patients did not
show existence of primary valvular disease and no patient was treated
by direct current shock before heart explantation.
Six non-diseased donor hearts were used as control (CNT) samples.
All donors had normal left ventricular function and no history of myo-
cardial disease or active infection at the time of transplantation. The
hearts were initially considered for cardiac transplantation but were sub-
sequently deemed unsuitable for transplantation either because of blood
type or size incompatibility. The cause of death was cerebrovascular
accident or motor vehicle accident.
Transmural samples were taken from near the apex of the left ventri-
cle (in the ischaemic patients we used the peri-infarct zone), maintained
in 0.9% NaCl throughout the extraction procedure and stored at 4°C for
a maximum of 6 hrs from the time of coronary circulation loss. All tis-
sues were obtained with informed consent of patients.
All patients gave written informed consent to participate in the study.
The project was approved by the local Ethics Committe (Biomedical
Investigation Ethics Committe of “La Fe “Universitary Hospital of Valen-
cia, Spain) and the research was carried out according to the World
Medical Association Declaration of Helsinki.
Tissue homogenization
Frozen ventricular tissue was homogenized using a mortar and a pestle,
in 400 ll lysis buffer [50 mM Tris-HCl (pH 7.4), 0.5 mM ethylenedi-
aminetetraacetic acid, 1.25 mM dithiothreitol (DTT) and 0.5% Tween 20]
supplemented with 4 ll phosphatase inhibitor cocktail (Sigma-Aldrich,
Madrid, Spain) and 4 ll protease inhibitor cocktail (Sigma-Aldrich). The
homogenate was sonicated twice, with 5 sec pulses (Sonifier 150, Bran-
son, Emerson, MO, USA). Then, it was centrifuged at 10,000 g for
10 min. and the pellet was discarded. For protein extraction, 100 ll of
supernatant was subjected to precipitation [2-D Clean-Up kit, GE Health-
care (Uppsala, Sweden)] according to the manufacturer’s protocol.
The resulting protein pellet was then resuspended in 50 ll 2D sample
buffer [5 M urea, 2 M thiourea, 2 mM tributyl-phosphine, 65 mM DTT,
4% (w/v) 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
(CHAPS), 1.6% (w/v) dimethylbenzylammonium propane sulfonate-256
(NDSB-256)] and stored at 20 °C. The protocol followed was applied
after comparing the different protein extraction methods which involved
different homogenization techniques (data not shown), making sure that
the resulting pellet only included non-homogenate tissue.
Two-dimensional gel electrophoresis
Protein quantitation was carried out with the Coomassie Plus protein
reagent (Thermo Scientific, Asheville, NC, USA). For each sample,
300 lg of protein was resuspended in 300 ll of 2D sample buffer.
Before passive rehydration of immobilized pH gradient (IPG) strips (3–
10 Non-Linear, 18 cm, GE Healthcare), ampholytes were added to the
sample at 0.1% Servalyte 3–10, 0.05% Servalyte 2–4 and 9–11
(SERVA, Germany). Isoelectric focusing was achieved in a Protean IEF
cell (BioRad, CA, USA) following the manufacturer’s protocol. Succeed-
ing focusing, the IPG strips were immediately equilibrated for 10 min.
in equilibration buffer (4 M urea, 2 mM thiourea, 12 mM DTT, 50 mM
Tris pH 6.8, 2% SDS, 30% glycerol). The IPG strips were placed on top
of the second dimension gels and embedded with 1% melted agarose.
Proteins were separated in the second dimension by SDS-PAGE on
12.5% gels at running conditions of 18°C, 20 mA per gel for 16 hrs
using Proteome Plus Dodeca cell (BioRad). Following electrophoresis,
gels were fixed in 10% methanol/7% acetic acid for 1 hr, and stained
16 hrs with Sypro Ruby fluorescent dye (Lonza, Switzerland). After
staining, gels were washed for 1 hr in 10% methanol/7% acetic acid
and scanned in a Typhoon 9410 (GE Healthcare).
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Differential image analysis
The scanned gel images corresponding to CNT, ICM and DCM samples
were sent to the Ludesi Analysis Center (Lund, Sweden, http://www.lude-
si.com) for professional image analysis performed with Ludesi REDFIN 3
software. Spot detection, segmentation and matching followed a strict
protocol to ensure a high level of correctness. Gels were matched using
all-to-all spot matching, avoiding the bias caused by the use of a reference
gel. Manual editing of spots was performed when needed. The integrated
intensity of each of the spots was measured, and the background cor-
rected and normalized. Spot volumes were normalized to the sum of all
spot volumes in the gel image. Normalization removes systematic gel
intensity differences originating, for example, from variations in staining,
scanning time and protein loading by mathematically minimizing the med-
ian expression difference between matched spots. This allows a satisfac-
tory quantification and comparison of different gels. Differential
expression of spots was defined on the basis of >1.75-fold change
between group averages and P < 0.05 [10]. Differences involving at least
94% of the samples of each group were considered meaningful.
Mass spectrometric analysis
Spots chosen for mass spectrometric analysis were excised from the
gels and manually in-gel digested with trypsin (Promega, Madison, WI,
USA) as described previously [15]. Spots were reduced with DTT and
alkylated with iodoacetamide prior to trypsin digestion. For mass spec-
trometry (MS) analysis, dried peptides were dissolved in 3 ll of 0.5%
HCOOH. Equal volumes (0.5 ll) of peptide and matrix solution, consist-
ing of 3 mg CHCA dissolved in 1 ml of 50% acetonitrile in 0.1% triflu-
oroacetic acid, were deposited using the thin layer method onto a 384
Opti-TOF (Time of Flight) MALDI (Matrix Assisted Laser Desorption/Ion-
ization) plate (Applied Biosystems, CA, USA). Mass spectrometric data
were obtained in an automated analysis loop using 4800 MALDI-TOF/
TOF analyzer (Applied Biosystems). The MS spectra were acquired in
reflectron positive-ion mode with a Nd:YAG, 355 nm wavelength laser,
averaging 1000 laser shots and at least three trypsin autolysis peaks
were used as internal calibration. All MSMS spectra were performed by
selecting the precursors with a relative resolution of 300 (Full Width at
Half Maximum) and metastable suppression. Automated analysis of
mass data was achieved using the 4000 Series Explorer software v3.5.
The MS and MSMS spectra data were combined through the Global
Proteome Server Explorer software v3.6 using Mascot software v2.1
(Matrix Science) to search against a non-redundant database (Swiss-
Prot release 56.0), with 30 p.p.m. precursor tolerance, 0.35 Da MSMS
fragment tolerance and allowing 1 missed cleavage. Protein scores
greater than 56 were accepted as significant (P < 0.05), considering
positive the identification whose protein score Confidence Interval %
(CI) was above 98. In the case of MSMS spectra, total ion score CI%
was above 94.
Western blotting analysis
For 2D Western blot analysis, 80 lg of protein was resuspended in
120 ll of 2D sample buffer and isoelectrofocusing were performed in IPG
strips 3–10 Non-Linear, 7 cm (BioRad), following the manufacturer’s pro-
tocol. As described previously, IPG strips were placed on 12% SDS poly-
acrylamide gel and electrotransferred onto nitrocellulose membranes
Table 1 Clinical and echocardiographic characteristics according to
heart failure aetiology
ICM
(n = 12)
DCM
(n = 12)
Age (years) 55 ± 7 44 ± 10†
Gender male (%) 100 100
BMI (kg/m2) 28 ± 3 27 ± 4
Prior hypertension (%) 45 25
Prior smoking (%) 100 58*
Diabetes mellitus (%) 64 0†
NYHA class 3.6 ± 0.4 3.5 ± 0.4
Haemoglobin (mg/dl) 14 ± 2 13 ± 1
Haematocrit (%) 42 ± 5 41 ± 5
Total cholesterol (mg/dl) 161 ± 41 142 ± 41*
Duration of disease (months) 57 ± 44 52 ± 43
Number of myocardial infarctions 1.5 ± 0.7 0*
Echo-Doppler study
Ejection fraction (%) 23 ± 4 19 ± 7
Fractional shortening (%) 13 ± 4 10 ± 4
Left ventricular end systolic
diameter (mm)
55 ± 9 72 ± 7‡
Left ventricular end diastolic
diameter (mm)
64 ± 9 81 ± 8‡
Left ventricle mass (g) 253 ± 69 403 ± 126†
Left ventricle mass index (g/cm2) 133 ± 30 201 ± 48†
Treatment (%)
Diuretics 92 92
Aldosterone antagonists 75 92
b-blockers 58 92
Angiotensin-converting enzyme
inhibitors
67 67
Digoxin 50 50
Statins 67 17*
Duration of disease from diagnosis of heart failure until heart trans-
plant.
BMI: body mass index; DCM: dilated cardiomyopathy; NYHA: New
York Heart Association.
*P < 0.05;
†P < 0.01;
‡P < 0.0001.
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(HyBond, GE Healthcare). The primary detection antibodies used were:
anti-GAPDH monoclonal antibody (1:10000) and anti-HSPA1B monoclo-
nal antibody (1:15000), from AbCam (Cambridge, UK), heretofore
blocking them in 5% bovine serum albumin (BSA) in Tris Buffered Saline
(TBS-T). Membranes were exposed to horseradish peroxidase-labelled
goat antimouse antibody (1:2000) (Santa Cruz Biotechnology, Inc., Dela-
ware, CA, USA) and processed using an enhanced chemiluminiscence
system (Immobilon Western, Millipore Corporation, MA, USA).
Fluorescence microscopy
Frozen muscular sections were transferred to glass slides, fixed in 4%
paraformaldehyde for 15 min. at 4°C. Then samples were blocked with
PBS containing 1% BSA for 15 min. at room temperature. After block-
ing, sections were incubated for 120 min. at room temperature with the
primary antibodies (described in western blot analysis) in the same buf-
fer solution, and then with fluorescein isothiocyanate (FITC)-conjugated
secondary antibody (Santa Cruz Biotechnology INC) for 60 min. at room
temperature [16]. Finally, sections were rinsed in PBS, mounted in Vec-
tashield conjugated 4′,6-diamidino-2-phenylindole (DAPI) for identifying
nucleous (Vector Laboratories, CA, UK), and observed with an Olympus
BX50 fluorescence microscope (Tokyo, Japan). The images were pro-
cessed with ImageJ (v. 1.4.3.67) program.
Ingenuity Pathways Analysis
Ingenuity Pathways Analysis software (Ingenuity Systems, CA, USA)
was used to investigate possible interactions between all the identified
proteins common in both aetiologies. Interactive pathways were gener-
ated to observe potential direct and indirect relations among the differ-
entially expressed proteins.
Statistical methods
Data are presented as the mean value ± standard deviation. The Kol-
mogorov-Smirnov test was used to analyse the distribution of the vari-
ables. Comparisons of clinical characteristics were achieved using
Student’s t-test for continuous variables and Fisher exact test for dis-
crete variables. Comparison of protein expression levels between groups
was performed with the normalized spot volumes and applying the
Mann–Whitney U-test. Significance was assumed as P < 0.05. All sta-
A B
C
Fig. 1 2-DE-based proteome analysis of LV tissue from patients with ICM and DCM. Representative 2-DE image of LV tissue proteins of ICM, DCM
and CNT samples (3–10 pH range, 12.5% SDS polyacrylamide gel in the second dimension) (A). Black arrowheads indicate spots with higher
expression levels, whereas white arrowheads designate under-expression spots. In both cases compared with CNT (B, C). CNT: control; DCM:
dilated cardiomyopathy; ICM: ischaemic cardiomyopathy; LV: left ventricular.
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Table 2 Ventricle proteins differentially regulated in CNT versus ICM patients
Spot Protein Accesion number Fold-change P-value Function
29 ATP synthase subunit O, mitochondrial ATPO_HUMAN +3.20 0.0048 Respiratory chain
43 NADH dehydrogenase [ubiquinone] iron-sulphur
protein 4, mitochondrial
NDUS4_HUMAN 1.81 7.630e4 Respiratory chain
66 Ig gamma-1 chain C region IGHG1_HUMAN +3.48 0.0048 Immune response
86 Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN +2.53 1.077e4 Metabolism
99 Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN +1.97 4.259e4 Metabolism
102 Adenylate kinase 2, mitochondrial KAD2_HUMAN 1.93 0.0021 Metabolism
115 Adenylate kinase 2, mitochondrial KAD2_HUMAN 3.75 4.259e4 Metabolism
141 NADH dehydrogenase [ubiquinone] 1 beta
subcomplex 9
NDUB9_HUMAN +3.30 0.0021 Respiratory chain
146 Protein NipSnap homolog 3A NPS3A_HUMAN 2.59 0.0134 Miscellaneous
196 Electron transfer flavoprotein-ubiquinone
oxidoreductase, mitochondrial
ETFD_HUMAN +2.27 0.0097 Transport
Dihydrolipoyl dehydrognease, mitochondrial DLDH_HUMAN Metabolism
197 ATP synthase subunit alpha, mitochondrial ATPA_HUMAN +5.19 1.077e4 Respiratory chain
211 Dihydrolipoyl dehydrogenase, mitochondrial DLDH_HUMAN +2.92 1.077e4 Metabolism
228 Succinyl-CoA:3-ketoacid-coenzyme A transferase 1,
mitochondrial
SCOT1_HUMAN +4.35 2.173e4 Metabolism
239 Malate dehydrogenase, cytoplasmic MDHC_HUMAN 2.31 4.259e4 Metabolism
318 ES1 protein homolog, mitochondrial ES1_HUMAN 2.37 0.0182 Miscellaneous
326 3-hydroxyacyl-Coa dehydrogenase type-2 HCD2_HUMAN 3.11 2.173e4 Metabolism
333 Alpha-crystallin B chain CRYAB_HUMAN 1.98 0.0321 Structural
344 Myoglobin MYG_HUMAN 2.48 1.077e4 Transport
Peptidyl-prolyl cis-trans isomerase A PPIA_HUMAN Immune response
352 D-dopachrome decarboxylase DOPD_HUMAN 2.28 0.0021 Metabolism
363 Ezrin EZRI_HUMAN +3.05 1.077e4 Structural
460 Ig kappa chain C region IGKC_HUMAN +2.18 0.0244 Immune response
476 Cytochrome c1, haem protein, mitochondrial CY1_HUMAN +3.31 0.0097 Respiratory chain
489 Cytochrome b-c1 complex subunit Rieske,
mitochondrial
UCR1_HUMAN 1.79 0.0244 Respiratory chain
490 Cytochrome b-c1 complex subunit Rieske,
mitochondrial
UCR1_HUMAN 1.91 7.630e4 Respiratory chain
534 Heat shock 70 kD protein 1 HSP71_HUMAN +3.31 4.259e4 Stress response
540 Stress-70 protein, mitochondrial GRP75_HUMAN +1.64 1.077e4 Stress response
628 Glutathione S-transferase Mu 3 GSTM3_HUMAN 2.29 4.259e4 Metabolism
629 Peroxiredoxin-2 PRDX2_HUMAN +2.96 0.0048 Stress response
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tistical analyses were performed with SPSS software v. 15 for Windows
(SPSS Inc.).
Results
Clinical characteristics of patients
All patients were men with a mean age of 49 ± 10 yrs. These patients
had a NYHA functional classification of III–IV and were previously
diagnosed with significant comorbidities including hypertension,
hypercholesterolemia, obesity and diabetes mellitus. The clinical and
echocardiographic characteristics of patients according to HF aetiol-
ogy are summarized in Table 1. The DCM group was significantly
younger compared with ICM patients (P < 0.01). Significant differ-
ences were also found in left ventricular end systolic diameter
(P < 0.0001), left ventricular end diastolic diameter (P < 0.0001), left
ventricular mass (P < 0.01) and left ventricular mass index
(P < 0.01) as an increase in the DCM compared with ICM group. No
statistically significant changes were found in the different drugs
administered according to aetiology of HF, except for statins
(P < 0.05). Six non-diseased donor hearts were used as control
(CNT) samples (67% male, mean age 49 ± 16 yrs, ejection frac-
tion >50%).
Proteome analysis of left ventricular tissue by
2D electrophoresis
We performed 2D gel electrophoresis (2DE) to expand our knowledge
on the proteome changes associated with ICM and DCM. The prote-
ome analysis was carried out on left ventricular tissue of patients with
HF. After the optimization of the experimental conditions for tissue
homogenization, protein extraction and separation by 2DE, we stan-
dardized experimental conditions resulting in reproducible 2D gels
(18 9 19 cm) for 3–10 NL pH gradient. We detected a mean of
876 ± 56.7 spots corresponding to left ventricular tissue from CNT,
900 ± 43.2 from ICM and 895 ± 39.7 from DCM.
Thirty gels, six from CNT samples, and 12 for each cardiomyo-
pathy (12 ICM and 12 DCM) were submitted to differential image
analysis. We focused on the identification of up- and down-regula-
tion of spot intensities where the fold change was at least 1.75
(with P < 0.05). Furthermore, for the analysis we only considered
spots that were present in at least 94% of the gels in a given group
(CNT, ICM or DCM). These conservative criteria for protein detec-
tion aimed to avoid misidentifications due to gel-to-gel variation.
Taking into account these conservative criteria, we encountered 35
differentially regulated spots in the comparison of CNT versus ICM
(Fig. 1A), 33 in CNT versus DCM (Fig. 1B), and 34 in ICM versus
DCM. All were successfully identified by MS (Tables S1, S2 and
S3, respectively).
In the case of the 35 ICM spots identified, 15 protein features
were down-regulated, while 20 were up-regulated. They correspond
to 33 open reading frames (ORFs), with four ORFs being represented
by two spots (86 and 99; 102 and 115; 196 and 211; 489 and 490).
The 33 spots with differential expression in DCM correspond to 31
ORFs, with three ORFs being represented by two spots (66 and 69;
196 and 211; 789 and 811) and one ORF represented by three spots
(86, 87 and 868). Nine spots were down-regulated in DCM gels,
whereas 24 were up-regulated. We identified spots with more than
one protein, concretely, spots 196 and 344 in ICM (Table 2) and
spots 204, 339 and 366 in DCM (Table 3), as a result of coincidence
in pI and molecular weight.
The comparison between pathological groups (ICM and DCM)
shows 34 differentially expressed spots, 14 up-regulated in ICM and
20 in DCM. They correspond to 33 ORFs, three of them represented
by two spots (165 and 496; 326 and 460; 788 and 811), due to the
existence of isoforms. We identified more than one protein in spots
18 and 788, as a consequence of their common pI and Mw.
Table 2. Continued
Spot Protein Accesion number Fold-change P-value Function
640 Heat shock protein beta-1 HSPB1_HUMAN 2.39 4.259e4 Stress response
649 Prohibitin PHB_HUMAN +2.25 2.173e4 Miscellaneous
678 Heat shock protein beta-6 HSPB6_HUMAN 1.76 2.173e4 Stress response
739 Alpha-1-antitrypsin A1AT_HUMAN +2.43 1.077e4 Miscellaneous
878 Heat shock cognate 71 kD protein HSP7C_HUMAN +2.61 0.0048 Stress response
890 NADH dehydrogenase [ubiquinone]
iron-sulphur protein 3, mitochodrial
NDUS3_HUMAN +2.51 0.0097 Respiratory chain
907 Aconitase hydratase, mitochondrial ACON_HUMAN +3.92 4.259e4 Metabolism
A negative-fold change indicates that the protein feature is down-regulated in ICM whereas a positive-fold change indicates the spot is up-regu-
lated in this pathological group. The proteins shown in bold are altered in both ICM and DCM aetiology.
CNT: control; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy.
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Table 3 Ventricle proteins differentially regulated in CNT versus DCM patients
Spot Protein Accesion number Fold-change P-value Function
23 ATP synthase subunit G, mitochondrial ATPG_HUMAN +3.71 1.077e4 Respiratory chain
29 ATP synthase subunit O, mitochondrial ATPO_HUMAN +3.79 7.630e4 Respiratory chain
66 ATP synthase subunit A, mitochondrial ATPA_HUMAN +3.25 1.077e4 Respiratory chain
69 ATP synthase subunit A, mitochondrial ATPA_HUMAN +2.31 0.0069 Respiratory chain
78 UTP-glucose-1-phosphate urydylyltransferase UGPA_HUMAN +3.19 1.077e4 Metabolism
86 Annexin A2 ANXA2_HUMAN +2.19 4.259e4 Transport
87 Annexin A2 ANXA2_HUMAN +3.90 1.077e4 Transport
94 Acetyl-CoA acetyltransferase, mitochondrial THIL_HUMAN +2.30 0.0097 Metabolism
107 Glyceraldehyde-3-phosphate dehydrogenase G3P_HUMAN +2.89 2.173e4 Metabolism
141 NADH dehydrogenase [ubiquinone] 1 beta
subcomplex subunit 9
NDUB9_HUMAN +2.23 0.0021 Respiratory chain
196 Dihydrolipoyl dehydrogenase, mitochondrial DLDH_HUMAN +2.25 0.0097 Metabolism
197 Glutamate dehydrogenase 1, mitochondrial DHE3_HUMAN +2.91 7.630e4 Metabolism
204 Aspartate aminotransferase, cytoplasmic AATC_HUMAN +1.99 2.173e4 Metabolism
Alpha-enolase ENOA_HUMAN Metabolism
211 Dihydrolipoyl dehydrogenase, mitochondrial DLDH_HUMAN +2.10 0.0048 Metabolism
252 Alcohol dehydrogenase [NADP+] AK1A1_HUMAN 4.74 1.077e4 Metabolism
312 Alpha-crystallin B chain CRYAB_HUMAN 2.10 0.0021 Structural
330 THAP domain-containing protein 4 THAP4_HUMAN 1.92 0.0032 Miscellaneous
339 Peroxiredoxin-5 PRDX_HUMAN 2.02 0.0021 Stress response
Peptidyl-prolyl cis-trans isomerase PPIA_HUMAN Immune response
366 Mitochondrial inner membrane protein IMMT_HUMAN +3.13 0.0069 Miscellaneous
Ezrin EZRI_HUMAN Structural
447 Metaxin-2 MTX2_HUMAN 2.48 0.0097 Transport
489 Cytochrome b-c1 complex subunit Rieske,
mitochondrial
UCR1_HUMAN 2.66 4.259e4 Respiratory chain
540 Stress-70 protein, mitochondrial GRP75_HUMAN +1.75 1.077e4 Stress response
601 Stomatin-like protein 2 STML2_HUMAN +2.02 0.0182 Structural
611 Glyoxalase domain-containing protein 4 GLOD4_HUMAN 3.53 0.0013 Miscellaneous
629 Ubiquitin carboxyl-terminal hydrolase isozyme L1 UCHL1_HUMAN +2.32 0.0097 Miscellaneous
649 Prohibitin PHB_HUMAN +1.93 0.0021 Miscellaneous
Chloride intracellular channel protein 4 CLIC4_HUMAN Transport
721 Alpha-2-HS-glycoprotein FETUA_HUMAN +3.38 0.0069 Miscellaneous
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In ICM, 82% of detected protein features showed a difference
of not more than 6 kD compared with the theoretical values calcu-
lated on the basis of the ORFs. Inspection of pI showed that 74%
of the spots had an experimental pI with no deviation over ± 0.5
from the theoretical value. In DCM, 76% exhibited a variation of
not more than 8 kD in comparison with the theoretical values, and
61% had an experimental pI with a maximum deviation of ± 0.5.
In the comparison between both pathologies, 52% showed a varia-
tion of not more than 8 kD in their Mw values with respect to their
theoretical values, and 24% revealed an experimental pI deviation
of ± 0.5, excluding Ig kappa chain C region with a shift of 15 kD,
resulting in fragmented immunoglobulin. In the case of significant
deviations in pI and Mw, we observed that they were a result of
the presence of isoforms and/or posttranslational modifications, e.
g. phosphorylation, glycations.
Significant proteins identified
We show in Tables 2 and 3 that many of the proteins involved in cel-
lular stress response, respiratory chain and cardiac metabolism are
altered in human hearts with ICM or DCM. Some of these changes
are common in both aetiologies, such as stress-70 protein mitochon-
drial, NADH dehydrogenase (ubiquinone) 1 beta subcomplex 9,
dihydrolipoyl dehydrogenase or glyceraldehyde-3-phosphate dehy-
drogenase (G3P). However, most of the proteins altered in both
groups with respect to control group do not match. Heat shock pro-
teins (HSP71, HSPB1, HSPB6, HSP7C) are altered only in ICM group.
The remaining proteins identified were basically structural or impli-
cated in transport and immune response, such as alpha-crystallin B
(CRYAB), myoglobin and peptidyl-prolyl cis-trans isomerase, respec-
tively. When we compared the two pathological groups (ICM versus
DCM), we identified new altered proteins that were not detected in the
previous comparisons, e.g. metabolic enzymes or structural proteins,
such as malate dehydrogenase or actin alpha cardiac muscle respec-
tively (Table 4).
A selection of the above proteins was validated by 2D western
blotting. We identified G3P in the 2-DE analysis, being present in two
very close spots with a pI difference of 0.56 units (see Fig. 1B, spots
86 and 99; 1C spot 107). These spots (Fig. 2A, 2B, 2C) were up-regu-
lated in HF samples (ICM and DCM, Tables 2 and 3). The 2D Western
blot analysis allows us the detection of changes in expression
(Fig. 2D), showing alterations in a spot cluster expression. In addi-
tion, we identified heat shock 70 kD protein 1 (HSP71) in the 2-DE
analysis only in the ischaemic group (Fig. 3A) and we validated the
proteomic result by 2D Western blotting using a specific antibody,
as shown in Figure 3B. The results were coincident with proteomic
analysis.
Immunofluorescence studies showed that G3P intensity was
higher in the nucleus than in the cytoplasm in the ischaemic and
dilated hearts (91% and 77% respectively). Pathological hearts had
an increase in nucleus intensity compared with control samples
(P < 0.01). Furthermore, HSP71 was distributed on both the cyto-
plasm and nucleus in the three groups, but a significant higher per-
centage of fluorescence was measured inside the nucleus than
outside (172% ischaemic, 62% controls, and 77% dilated hearts). Is-
chaemic group has an increase in nucleus intensity compared with
control samples (P < 0.01). Finally, immunofluorescence analysis
showed that CRYAB was distributed on cytoplasm and the intensity of
this protein was lower in ischaemic and dilated hearts compared with
control samples (P < 0.01). The results were also coincident with
proteomic analysis (Fig. 4).
Ingenuity Pathways Analysis software (Ingenuity Systems) was
used to investigate possible interactions between the identified pro-
teins common in both aetiologies to highlight predominant networks.
Networks obtained in the two groups analysed were similar. Ten of
the eleven differentially regulated proteins identified are intercon-
nected as a part of a common network related to DNA replication,
recombination and repair, energy production and nucleic acid metab-
olism (Fig. 5). Interestingly, seven of those proteins, besides present-
ing a known function in the cell, are also involved in cell death,
specifically G3P, CRYAB, ATP synthase subunit alpha, ezrin, stress-
70 protein, prohibitin and peptidyl-prolyl cis-trans isomerase A. All
these proteins are related directly or indirectly with huntingtin and this
calcium channel regulator plays an important role in cell death and
apoptosis.
Table 3. Continued
Spot Protein Accesion number Fold-change P-value Function
787 Calpain small subunit 1 CPNS1_HUMAN 4.33 2.173e4 Transport
789 Myosin light chain 3 MYL3_HUMAN 2.28 0.0134 Structural
811 Myosin light chain 3 MYL3_HUMAN 5.39 0.0021 Structural
846 Calreticulin CALR_HUMAN +2.14 0.0032 Stress response
868 Annexin A2 ANXA2_HUMAN +2.25 4.259e4 Transport
891 Flavin reductase BLVRB_HUMAN +3.34 0.0182 Metabolism
A negative-fold change indicates that the protein feature is down-regulated in DCM whereas a positive-fold change indicates the spot is up-regu-
lated in this pathological group. The proteins shown in bold are altered in both ICM and DCM aetiology.
CNT: control; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy.
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Table 4 Ventricle proteins differentially regulated in ICM versus DCM patients
Spot Protein Accesion number Fold-change P-value Function
18 Malate dehydrogenase, mitochondrial MDHM_HUMAN 2.41§ 0.0068 Metabolism
Succinyl-CoA ligase]GDP-forming] subunit
alpha, mitochondrial
SUCA_HUMAN Metabolism
70 Pyruvate kinase isozymes M1/M2 KPYM_HUMAN 2.93* 0.0014 Metabolism
78 UTP-glucose-1-phosphatase
uridylyltransferase
UGPA_HUMAN 2.03* 0.0100 Metabolism
110 Galectin-3 LEG3_HUMAN 1.99‡ 0.0014 Immune response
115 Adenylate kinase 2, mitochondrial KAD2_HUMAN 4.64** 1.000e4 Metabolism
121 2,4-dienoyl-CoA reductase, mitochondrial DECR_HUMAN 2.83* 0.0036 Metabolism
165 Nucleoside diphosphate kinase B NDKB_HUMAN 1.97† 1.000e4 Metabolism
192 Alpha-enolase ENOA_HUMAN 2.94† 0.0100 Metabolism
197 ATP synthase subunit alpha,
mitochondrial
ATPA_HUMAN 1.78* 2.746e4 Respiratory chain
228 Succinyl-CoA:3-ketoacid-coenzyme A
transferase 1, mitochondrial
SCOT1_HUMAN 2.06* 0.0023 Metabolism
239 Malate dehydrogenase, cytoplasmic MDHC_HUMAN 1.84† 3.712e4 Metabolism
283 Ig lambda-3 chain C regions LAC3_HUMAN 1.76‡ 0.0045 Immune response
300 Voltage-dependent anion-selective channel
protein 2
VDAC2_HUMAN 1.86† 0.0045 Transport
304 Immunoglobulin lambda-like polypeptide 5 IGLL5_HUMAN 2.23‡ 0.0145 Immune response
318 ES1 protein homolog, mitochondrial ES1_HUMAN 2.01† 0.0449 Miscellaneous
326 Ig kappa chain C region IGKC_HUMAN 2.08† 0.0100 Immune response
335 Cofilin-2 COF2_HUMAN 2.42† 0.0068 Structural
344 Myoglobin MYG_HUMAN 1.96† 1.000e4 Transport
447 Metaxin-2 MTX2_HUMAN 2.23§ 0.0242 Transport
460 Ig kappa chain C region IGKC_HUMAN 3.26* 2.746e4 Immune response
469 Delta(3,5)-Delta(2,4)-dienoyl-CoA
isomerase,mitochondrial
ECH1_HUMAN 1.79§ 0.0145 Metabolism
490 Cytochrome b-c1 complex subunit Rieske,
mitochondrial
UCRI_HUMAN 1.92† 1.446e4 Respiratory chain
496 Nucleoside diphosphate kinase A NDKA_HUMAN 1.76‡ 0.0011 Metabolism
553 Actin, alpha cardiac muscle ACTC_HUMAN 2.40§ 8.585e4 Structural
601 Stomatin-like protein 2 STML2_HUMAN 1.97‡ 0.0205 Sructural
611 Glyoxalase domain-containing protein 4 GLOD4_HUMAN 2.84§ 0.0056 Miscellaneous
640 Heat shock protein beta-1 HSPB1_HUMAN 2.37† 1.000e4 Stress response
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Table 4. Continued
Spot Protein Accesion number Fold-change P-value Function
739 Alpha-1-antitrypsin A1AT_HUMAN 1.77* 1.000e4 Miscellaneous
781 Tropomyosin alpha-4 TPM4_HUMAN 2.75‡ 2.746e4 Structural
788 Rho GDP-dissociation inhibitor 1 GDIR1_HUMAN 2.52† 0.0018 Signal Transduction
Myosin light chain 4 MYL4_HUMAN Structural
811 Myosin light chain 3 MYL3_HUMAN 3.67§ 0.0083 Structural
812 Lactoylglutathione lyase LGUL_HUMAN 1.87‡ 0.0242 Metabolism
890 NADH dehydrogenase [ubiquinone]
iron-sulphur protein 3, mitochondrial
NDUS3_HUMAN 2.99* 2.006e4 Respiratory chain
1198 Heterogeneous nuclear ribonucleoproteins
A2/B1
ROA2_HUMAN 3.49* 3.712e4 Transport
Note*Protein up-regulated in ICM,
†protein down-regulated in ICM,
‡protein up-regulated in DCM,
§protein down-regulated in DCM.
The number of fold-change is referred to the comparison between ICM and DCM. The direction of the fold-change values is referred to the pro-
tein levels of the CNT group. The proteins shown in bold were altered in any pathological group when we compared with CNT samples
(Tables 2 and 3).
CNT: control; DCM: dilated cardiomyopathy; ICM: ischaemic cardiomyopathy.
A B
C D
Fig. 2 G3P is over-expressed in patients with ICM and DCM contrasted to CNT samples. The volume of spots 86 and 99 (white outline) in ICM
(n = 12) shows a higher level of expression compared with CNT group (n = 6) (A, B). The volume of spot 107 (white outline) in DCM (n = 12)
shows a higher level of expression compared with CNT (C). Representative image of 2D Western blot reveals an alteration in G3P expression (black
arrowhead) between CNT and HF patients (D). Images are representative of the results obtained for all the patients included in the study. CNT: con-
trol; DCM: dilated cardiomyopathy; G3P: glyceraldehyde-3-phosphate dehydrogenase; ICM: ischaemic cardiomyopathy. *P < 0.0001.
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Discussion
In the present study, we carried out a 2DE-based proteomic analysis
of ventricular tissue from patients with ICM and DCM to investigate
cardiac protein expression changes in HF, and to gain more knowl-
edge on the cellular mechanisms related to the development of HF.
Previous works on proteomic analysis in cardiac tissue from patients
with HF are limited [4–9]. To date, proteomic investigations into heart
disease have preferably focused on failing hearts due to DCM. In fact,
to the best of our knowledge there are only two proteomic studies
performed on human left ventricular tissue from patients with ICM
and DCM [7, 8]. We want to emphasize the importance of having car-
ried out this study in a significant number of samples from explanted
human hearts from patients with ICM and DCM undergoing cardiac
transplantation. This has allowed us to extract the region of tissue
that we want to analyse, which could not have been possible if the
study had been made with biopsies. In particular, our study showed a
large number of proteins involved in cellular stress response, respira-
tory chain and cardiac metabolism that are altered in heart failure
compared with the non-failing hearts.
We found 35 spots to be differentially regulated between left ven-
tricular tissue from ICM and control group (20 increased, 15
decreased), and a total of 33 spots were altered in DCM (24 up-regu-
lated, 9 down-regulated). We have shown that many of the underex-
pressed proteins in ICM are implicated in mitochondrial function, and
it is known that mitochondrial dysfunction is involved in a variety of
pathologies including heart disease and ischaemia/reperfusion [17].
We also found that some mitochondrial proteins increased in both
aetiologies, concretely ATP synthase subunit O, ATP synthase subunit
alpha, NADH dehydrogenase (ubiquinone) 1 alpha subcomplex sub-
unit 10, dihydrolipoyl dehydrogenase, stress-70 protein and prohib-
itin. Mitochondria are a major source and target of free radicals and
the collapse of the mitochondrial transmembrane potential can initiate
the signaling cascades involved in apoptosis [18]. In addition, it plays
an important role in the regeneration of antioxidants and it is respon-
sible for the majority of ATP production [19]. Thus, characterization
of the mitochondrial proteome could provide new insights into car-
diac dysfunction in heart failure patients [17, 20, 21].
It is well known that certain proteins, including myoglobin, called
serum cardiac markers, are released into the bloodstream in large
quantities from necrotic cardiac muscle cells after myocardial infarc-
tion [22–24]. As direct samples from the ischaemic region are not
readily obtainable, in situ studies of this protein in the cardiac ischae-
mic region have been limited [25]. We found myoglobin to be down-
regulated in left ventricular tissue of patients with ICM. These results
are consistent with those published by Dohko et al. in an experimen-
tal model of HF [12]. Myoglobin is not only important in intracellular
oxygen supply but also constitutes a key element that influences vari-
ous redox pathways in the muscle cell [26]. It seems likely that the
multifunctional character of this protein creates an environment char-
acterized by a tightly adapted aerobic mitochondrial respiration and
low levels of free radicals, and thus plays an essential and beneficial
role within the myocardium [27]. The underlying mechanisms by
which myoglobin content decreases in failing myocardium are
unknown but the decrease in this protein may contribute to the imbal-
ance between energy production and energy expenditure in HF.
Myocytes compensate for the alteration in mitochondrial function
by an increase in glycolysis-related proteins [28]. Changes in the
expression of a variety of proteins involved in energy metabolism
have been detected in HF by performing proteome analysis [29] and
our results are in concordance with these studies. We found altera-
tions in different proteins associated with metabolism in patients with
ICM and DCM. Moreover, we have shown that some of them are over-
expressed in both aetiologies, such as G3P and dihydrolipoyl dehy-
drogenase. The G3P is an ubiqitously expressed glycolytic enzyme
essential for efficient energy production [30] and it is involved in cel-
lular hypoxic and oxidative response [31], apoptosis [32], microtu-
bule organization [33] and RNA-binding [34]. Increased levels of this
protein have been found in spontaneous canine DCM [35] and in
other experimental models of HF in which myocardial infarction was
induced [12]. However, for the first time to the best of our knowledge,
we have identified high levels of G3P in left ventricular tissue from
patients with HF and we decided to focus on it. Furthermore, these
results question the uselfulness of this protein as loading control in
patients with HF. Immunofluorescence studies showed that G3P
intensity was higher in the nucleus than in the cytoplasm in the is-
chaemic and dilated hearts. Apoptosis plays an important role in the
remodelling of the myocardium in response to haemodynamic load
[36] and HF is associated with increased free radical production,
which leads to a state of oxidative stress [37]. There is evidence indi-
cating that nuclear translocation of G3P plays a role in apoptosis and
oxidative stress in neurodegenerative diseases, probably related to
A
B
Fig. 3 The HSP71 is over-expressed in patients with ICM contrasted to
CNT samples. Spot 534 volumes (white outline) in CNT (n = 6) and
patients with ICM (n = 12), exhibiting an expression increase in ischae-
mic samples compared with CNT (A). Representative image of 2D Wes-
tern blot reveals an alteration in HSP71 expression between CNT and
patients with ICM (B). Images are representative of the results obtained
for all the patients included in the study. CNT: control; HSP71: heat
shock 70 kD protein 1; ICM: ischaemic cardiomyopathy. *P < 0.0001.
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the activity of this protein as a DNA repair enzyme or as a nuclear car-
rier for pro-apoptotic molecules [38–41]. In this regard, we can think
that in HF patients this translocation of G3P from the cytosol to the
nucleus could also occur.
HSP71 is a protein involved in cellular recovery, survival and
maintenance of cellular function [42]. Reports on the levels of HSP71
in HF patients due to ICM and DCM are contradictory. Specifically, it
was reported that HSP71 levels were not increased significantly in
DCM failing hearts compared with non-failing hearts [43]. Aversely, in
a posterior study high levels of HSP71 were documented in the myo-
cardium of HF patients with DCM [44]. In addition, increased serum
levels of HSP71 were associated with a low prevalence of ICM [45],
while other authors have shown increased serum HSP71 levels asso-
ciated with a higher prevalence of ICM and DCM [46]. Corbett et al.
showed increased expression of this protein in ICM [7]. Wei et al.
demonstrated significant up-regulation of cardiac and serum HSP71
in ICM and DCM [8] and they observed in cultured cardiomyocytes
pretreated with hypoxia to mimic the in vivo conditions of the myo-
cardium in response to myocardial damage, a significantly elevation
of intracellular and extracellular HSP71. Our results indicate that
HSP71 is increased only in the ischaemic group. In addition, immuno-
fluorescence studies showed that the ischaemic group had increased
nuclear intensity. The expression of HSPs is induced by heat and by a
variety of other cellular stresses including ischaemia and hypoxia.
The heat shock or stress response is characterized by both an
increase in transcription and translation of HSP70 family proteins,
and nuclear translocation of the protein [47–49]. Studies have shown
that cardiac ischaemia causes transient nuclear accumulation of
HSP71 and HSP72 [47, 48]. These works indicate that HSPs may sta-
bilize damaged proteins found within the nucleus after an acute
stress, such as ischaemia. With the aim of screening differences
between the two pathological groups, we compared them, noting that
most of the altered proteins that were common in previous compara-
tives of each aetiology (pathological group versus controls) do appear
in these comparative, no statistical difference was found (e.g. CRYAB,
G3P). Moreover, we detected that proteins differentially expressed in
CNT versus ICM or CNT versus DCM, were also altered in ICM versus
DCM and in the same way. However, the most remarkable finding of
the comparison of both aetiologies was the differential expression of
proteins that did not appear altered when compared with the CNT
A B C D
E F G H
I J K L
Fig. 4 Effect of HF on cell distribution of G3P, HSP71 and CRYAB. Immunofluorescence for G3P (A–D), HSP71 (E–H) and CRYAB (I–L) according to
HF aetiology, ischaemic (ICM) and dilated (DCM) cardiomyopathy compared with control group (CNT). Yellow spots are the fluorescence of lipofus-
cin particles. The insertions show the nucleus co-stained with DAPI (blue). All the micrographs are representative of the results obtained in four
independent experiments for each group studied, ICM (n = 4), DCM (n = 4) and CNT (n = 4). The bar represents 10 lm. D, H, bar graph compar-
ing the fluorescence intensity into nucleus of G3P and HSP71 in ischaemic and dilated compared with control hearts. The values from the cytoplasm
were set to 100. The L, bar graph comparing the fluorescence intensity into cytoplasm of CRYAB in ischaemic and dilated compared with control
hearts. The values from the nucleus were set to 100. The data are expressed as mean ± S.D. of four experiments. *P < 0.01. CRYAB: alpha-crystal-
lin B; G3P: glyceraldehyde-3-phosphate dehydrogenase; HF: heart failure; HSP71: heat shock 70 kD protein 1.
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group, such as proteins involved in cell structure and muscle contrac-
tion, including actin alpha cardiac muscle, down-regulated in patients
with DCM. Alterations in the expression of these proteins affect myo-
cardial contractility, and it has been found that actin dysfunction
could lead to DCM [50].
It is noteworthy that in the present study most of the protein iden-
tified common in both aetiologies are interconnected on the same net-
work that primarily involves structural and metabolic proteins and
enzymes or transporters involved in respiratory chain. Interestingly,
most of those proteins are related with cell death, specifically G3P
increases apoptosis of eukariotic cells [51] and CRYAB is involved in
inhibition of apoptosis and decreases necrosis of ischaemic cardio-
myocites in cell culture [52, 53]. These proteins are related directly
with huntingtin and this calcium channel regulator plays an important
role in cell death and apoptosis in the brain. This interaction reaffirmed
the implication of G3P and CRYAB in the apoptosis process in other
cell types. Myocardial apoptosis represents a potential pathophysio-
logical mechanism in HF progression [54], in this sense we can think
that our results are consistent with previous data as proteins such as
G3P increase and CRYAB decrease in our pathological samples.
One limitation of this study is the intrinsic variability of the sam-
ples, given they originate from human hearts, whose conditions (treat-
ment they undergo) are not as standardized as those of studies using
cell cultures. However, in our study most patients in both groups (is-
chaemic and dilated) received drugs like diuretics, aldosterone-antag-
onists, b-blockers, angiotensin-converting enzyme inhibitors or
A B
Fig. 5 Analysis of differentially regulated proteins by Ingenuity Pathways Analysis software (Ingenuity Systems). Potential protein interactions
according to HF aetiology, ischaemic (A) and dilated (B) cardiomyopathy are shown in following network: DNA replication, recombination, and repair,
energy production, and nucleic acid metabolism. Proteins identified by differential analysis are shown as shaded nodes with their gene names. Solid
lines represent direct interactions, dotted represent indirect interactions. Arrows from one node to another indicated that this node acts upon the
other. Lines without arrows represent binding. Node shapes are: Double circle = complex or group, notched triangle = transporter, dia-
mond = enzyme, oval = transcription regulator, circle = other. The ANP32B, Acidic leucine-rich nuclear phosphoprotein 32 family member B; ATP
synthase subunit O, mitochondrial; ATP5A1, ATP synthase subunit alpha, mitochondrial; ATP5D, ATP synthase subunit delta, mitochondrial; ATP5E,
ATP synthase subunit epsilon, mitochondrial; ATP5F1, ATP synthase subunit b, mitochondrial; ATP5H, ATP synthase subunit d, mitochondrial;
ATP5I, ATP synthase subunit e, mitochondrial; ATP5J, ATP synthase-coupling factor 6, mitochondrial; ATP5J2, ATP synthase subunit f, mitochon-
drial; ATP5L, P synthase subunit g, mitochondrial; ATP5S, ATP synthase subunit s, mitochondrial; ATPAF1: ATP synthase mitochondrial F1 complex
assembly factor 1; ATPAF2: ATP synthase mitochondrial F1 complex assembly factor 2;CCDC15: Coiled-coil domain-containing protein 15; CHCHD2:
Coiled-coil-helix-coiled-coil-helix domain-containing protein 2: mitochondrial; CRYAB: Alpha-crystallin B chain; DHRS2: Dehydrogenase/reductase
SDR family member 2; DLD: Dihydrolipoyl dehydrogenase: mitochondrial; DNAJC19: Mitochondrial import inner membrane translocase subunit
TIM14; EZR: Ezrin; GADPH: Glyceraldehyde-3-phosphate dehydrogenase; GSS: Glutathione synthetase; HPCAL1: HPCAL1 protein; HSF4: Heat shock
factor protein 4; HSPA9: Stress-70 protein: mitochondrial; HTT: Huntingtin; LDHB: L-lactate dehydrogenase B chain; LDHB: L-lactate dehydrogenase
B chain; NDUFB9: NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 9; NDUFV2: NDUFV2 protein; Pgk: Phosphoglycerate kinase Pgk;
PHB: Prohibitin; PPIA: Peptidyl-prolyl cis-trans isomerase A; PPL: Ppl protein; SET: Protein SET.
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digoxin. Thus, it is very unlikely that the pharmacological treatment
would contribute to the different protein profiles observed. Moreover,
no statistically significant changes were found in the different drugs
administered according to aetiology of HF, except for statins. Never-
theless, patients treated with statins had a similar protein profile com-
pared with those not treated with this drug (data not shown).
In addition, there are limitations inherent to 2DE, such as the
under-representation of very hydrophobic proteins, principally mem-
brane proteins, and those above 100 kD. The use of zoom gels for
the basic region of the proteome (pH 6–11) could expand the prote-
ome study, allowing the identification of novel proteins. This is why
we failed to identify cytokine proteins (IL-6, TNF-alpha, etc.), receptor
expression (sTNF-R1, sTNF-R2, sFAS, etc.) and well-established HF
markers, for example, BNP and NT-proBNP, which we determined in
a previous study performed with Western blot techniques and mRNA
expression quantified by quantitative real-time polymerase chain
reaction (RT-PCR) in the same cardiac tissue [55]. Apart from this,
we have identified a great number of mitochondrial proteins and it
could be interesting to isolate mitochondria from left ventricular tis-
sue and submit them to 2DE to characterize proteins related with this
organelle.
In the present study, we have shown by proteomics analysis that
HF is associated with changes in proteins involved in cellular stress
response, respiratory chain and cardiac metabolism. Although we
have found altered expression of eleven proteins common to both is-
chaemic and dilated aetiology, we also observed different proteins
altered in both groups. Furthermore, we have shown that seven of
these eleven proteins are involved in cell death and apoptosis pro-
cesses, and therefore in HF progression. Understanding the proteome
will offer the real possibility of knowing the function of the cardiovas-
cular system in all of its complexity that should result in the discovery
of new diagnostic or prognostic biomarkers and the identification of
potential drug targets for the development of new therapeutic
approaches for combating HF.
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